--- title: AtaiBeckley N.V. - Startup Match Score & Focus Areas description: Is AtaiBeckley N.V. the right VC for you? See how their thesis aligns with your startup and discover more active investors focusing on mental health and novel therapeutics. --- [![Höpöhöpö_logo_black](https://27245214.fs1.hubspotusercontent-eu1.net/hubfs/27245214/H%C3%B6p%C3%B6h%C3%B6p%C3%B6_logo_black.png)](https://www.hopohopo.io/?hsLang=io) - [For Startups](https://www.hopohopo.io?hsLang=io) - For Investors & Accelerators - [Screen your deal flow with AI](https://www.hopohopo.io/for-investors?hsLang=io) - [Source deals from co-investors and accelerators](https://www.hopohopo.io/source-deal-flow?hsLang=io) - [Help your portfolio fundraise](https://www.hopohopo.io/portfolio-fundraising?hsLang=io) - [For BANs](https://www.hopohopo.io/business-angel-networks?hsLang=io) - [Pricing](https://www.hopohopo.io/pricing?hsLang=io) - Resources - [Maritime Venture program](https://maritime-venture.com/) - [Startup Fundraising Essentials](https://www.hopohopo.io/fundraising-essentials?hsLang=io) - Investor lists - [EdTech investors in Europe](https://www.hopohopo.io/edtech-investors?hsLang=io) - [FinTech investors in Europe](https://www.hopohopo.io/fintech-investors?hsLang=io) - [HealthTech investors in Europe](https://www.hopohopo.io/healthtech-investors?hsLang=io) - [Climate & Sustainability investors](https://www.hopohopo.io/climate-and-sustainability-investors?hsLang=io) - [Gaming investors](https://www.hopohopo.io/gaming-investors?hsLang=io) - [SpaceTech investors](https://www.hopohopo.io/spacetech-investors?hsLang=io) - [SportsTech investors](https://www.hopohopo.io/sporttech-investors?hsLang=io) - [Enterprise Software investors](https://www.hopohopo.io/enterprise-software-investors?hsLang=io) - [DefSec investors](https://www.hopohopo.io/defsec-investors?hsLang=io) - [Marine Tech investors](https://www.hopohopo.io/marinetech-investors?hsLang=io) - [Mobility investors](https://www.hopohopo.io/mobility-investors?hsLang=io) - [PropTech investors](https://www.hopohopo.io/proptech-investors?hsLang=io) - [Energy investors](https://www.hopohopo.io/energy-investors?hsLang=io) - [Top 10 Active investors in Berlin](https://www.hopohopo.io/top-investors-berlin?hsLang=io) [Log in](https://start.hopohopo.io/) [Sign up](https://start.hopohopo.io/?signup=true) # AtaiBeckley N.V. Overview AtaiBeckley N.V. is a clinical-stage biopharmaceutical company formed in November 2025 through the strategic combination of atai Life Sciences N.V. and Beckley Psytech Limited. The company focuses on developing effective, rapid-acting, and convenient treatments for mental health conditions, aiming to transform patient outcomes. Its pipeline includes novel therapies such as BPL-003 (mebufotenin benzoate nasal spray) for treatment-resistant depression, VLS-01 (buccal film DMT) for treatment-resistant depression, and EMP-01 (oral R-MDMA) for social anxiety disorder, all in Phase 2 clinical development. Additionally, AtaiBeckley is advancing a drug discovery program to identify non-hallucinogenic 5-HT2AR agonists for opioid use disorder and treatment-resistant depression. Is AtaiBeckley N.V. the right investor for your startup? Browse their investment focus, stage preferences, and geographic scope to see how well they align with your fundraising goals. Your full match score with AtaiBeckley N.V., along with a list of other relevant VCs, is available on Hopohopo.io. ## AtaiBeckley N.V. VC Fund ![AtaiBeckley N.V. logo](https://www.hopohopo.io/hubfs/ecosystem-logos-from-platform/13651-c5d1e1154b8a9b7550c6aeb419bbb525.png) ## Investment focus ### Product type - Drugs / Pharma ### Industries / verticals - Digital & Consumer health Stages Series B or later First ticket size US$150,000,000 - US$150,000,000 ## Contact information Associate Director Clinical Development Chandni Hindocha ![LinkedIn](https://27245214.fs1.hubspotusercontent-eu1.net/hubfs/27245214/H%C3%B6p%C3%B6h%C3%B6p%C3%B6%20-%20Website%20visuals/Icons/carbon_logo-linkedin-grey.svg) ![Email](https://27245214.fs1.hubspotusercontent-eu1.net/hubfs/27245214/H%C3%B6p%C3%B6h%C3%B6p%C3%B6%20-%20Website%20visuals/Icons/Sign-At--Streamline-Core.svg) VP, Commercial Berrak Selek ![LinkedIn](https://27245214.fs1.hubspotusercontent-eu1.net/hubfs/27245214/H%C3%B6p%C3%B6h%C3%B6p%C3%B6%20-%20Website%20visuals/Icons/carbon_logo-linkedin-grey.svg) ![Email](https://27245214.fs1.hubspotusercontent-eu1.net/hubfs/27245214/H%C3%B6p%C3%B6h%C3%B6p%C3%B6%20-%20Website%20visuals/Icons/Sign-At--Streamline-Core.svg) ## How to approach funds like AtaiBeckley N.V. When approaching AtaiBeckley, founders should highlight differentiated clinical data, robust translational science, and a clear regulatory strategy for neuropsychiatric indications. Demonstrating a strong understanding of the mental health treatment landscape and how your solution addresses unmet needs or improves patient access will resonate. Emphasize partnerships with leading academic or clinical institutions and a credible plan for advancing through clinical milestones, as AtaiBeckley values rigorous, evidence-driven development and scalable impact. ## Find the best-fitting investors for your startup Stop wasting weeks searching for the right investors. Upload your deck and get matched with investors who actually fit your startup — so you can focus on building, not chasing. [Find your investor matches](https://start.hopohopo.io/?signup=true) ![Investor funnel board](https://www.hopohopo.io/hubfs/Investor%20list%20web%20page%201.png) [Check the next investor profile](https://www.hopohopo.io/investors/olbia-invest?hsLang=io) × ![Hopohopo logo](https://27245214.fs1.hubspotusercontent-eu1.net/hubfs/27245214/HO-Logo_favicon.png) ## Check your match score in Hopohopo.io Check how well AtaiBeckley N.V. fits your startup and get a list of the best-fitting investors for your fundraising. [Sign up](https://start.hopohopo.io/?signup=true) × ![Hopohopo logo](https://27245214.fs1.hubspotusercontent-eu1.net/hubfs/27245214/HO-Logo_favicon.png) ## Check AtaiBeckley N.V. contact details in Hopohopo.io Browse all of the contacts related to AtaiBeckley N.V. and send emails directly from your funnel. [Sign up](https://start.hopohopo.io/?signup=true) - [For Startups](https://www.hopohopo.io/startups?hsLang=io) - [For Investors and Accelerators](https://www.hopohopo.io/business-angels-and-vcs?hsLang=io) - [For Business Angel Networks](https://www.hopohopo.io/business-angel-networks?hsLang=io) - [Blog](https://hopohopo.gitbook.io/fundraising-with-hopohopo/) ### Follow us ![Höpöhöpö_logo_white](https://27245214.fs1.hubspotusercontent-eu1.net/hubfs/27245214/H%C3%B6p%C3%B6h%C3%B6p%C3%B6_logo_white.png) © 2026 Hopohopo.io All rights reserved [Privacy Policy](https://www.hopohopo.io/privacy-policy?hsLang=io) [Terms of Service](https://www.hopohopo.io/terms-of-service?hsLang=io) ![](https://px.ads.linkedin.com/collect/?pid=4090745&fmt=gif) ```json { "@context" : "https://schema.org", "@type" : "Organization", "description" : "AtaiBeckley N.V. is a clinical-stage biopharmaceutical company formed in November 2025 through the strategic combination of atai Life Sciences N.V. and Beckley Psytech Limited. The company focuses on developing effective, rapid-acting, and convenient treatments for mental health conditions, aiming to transform patient outcomes. Its pipeline includes novel therapies such as BPL-003 (mebufotenin benzoate nasal spray) for treatment-resistant depression, VLS-01 (buccal film DMT) for treatment-resistant depression, and EMP-01 (oral R-MDMA) for social anxiety disorder, all in Phase 2 clinical development. Additionally, AtaiBeckley is advancing a drug discovery program to identify non-hallucinogenic 5-HT2AR agonists for opioid use disorder and treatment-resistant depression.", "logo" : "https://148519842.fs1.hubspotusercontent-eu1.net/hubfs/148519842/ecosystem-logos-from-platform/13651-c5d1e1154b8a9b7550c6aeb419bbb525.png", "name" : "AtaiBeckley N.V.", "sameAs" : [ "", "" ], "url" : "https://www.ataibeckley.com" } ```